YOUR SEARCH FOR Text 19 RESULTS
11 of Total
Incyte in 2026 and Beyond | Incyte Stories
… more than $10B in potential peak net sales by 2030. 2026 will be a defining year as we …
12 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… neoplasms (MLN): Phase 2 (FIGHT‑203) Glioblastoma: Phase 2 in preparation NSCLC: …
13 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… track to achieve over ten impactful launches by 2030.” Key Recent Company Updates In October, …
14 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… neoplasms (MLN): Phase 2 (FIGHT‑203) Glioblastoma: Phase 2 (FIGHT-209) being …
15 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
View all news Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs October 31, 2023 at 7:00 AM EDT PDF
16 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… to have more than 10 high impact launches by 2030; the disease modifying/curative potential …
17 of Total
Medical Information Contact Info US & European Locations | Incyte.com
… 01 70 76 06 36* Germany 08001009633 089 20301 0899* Ireland 1800456748 Italy …
18 of Total
Let’s Talk Anal Cancer | Incyte Stories
December 11, 2025 Let’s Talk Anal Cancer More than 10,000 people in the U.S. faced an anal cancer diagnosis last year. 1 While anal cancer is rare,
19 of Total
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
View all news Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs November 1, 2022 at 7:00 AM EDT PDF